Rare & Genetic · Clinical trials
Sickle Cell Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About sickle cell disease — and why its trials are hard
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the beta-globin gene that produces hemoglobin S, which polymerizes when deoxygenated, deforming red cells into rigid sickle shapes. This drives chronic hemolytic anemia and recurrent, painful vaso-occlusive crises (VOCs), progressive organ damage, and shortened life expectancy. Hydroxyurea, which raises protective fetal hemoglobin, has been the foundational disease-modifying therapy for decades. More recent additions include L-glutamine (Endari) to reduce oxidative stress, voxelotor (Oxbryta), a hemoglobin oxygen-affinity modulator, and crizanlizumab (Adakveo), a P-selectin monoclonal antibody to prevent VOCs. Notably, voxelotor was voluntarily withdrawn from the market in 2024 over safety concerns. The landmark 2023 approvals of gene therapies exagamglogene autotemcel (Casgevy, a CRISPR-based therapy) and lovotibeglogene autotemcel (Lyfgenia) offer potentially curative, one-time treatment by reducing or eliminating VOCs. These therapies mark a shift from symptom management toward durable, transformative cures, though access, cost, and conditioning-related risks remain challenges.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Hydroxyurea (Droxia / Siklos) | 1998 | Reduction of painful crises in adults (later pediatric) with SCD | MSH (Multicenter Study of Hydroxyurea) | Frequency of painful crises | ~50% reduction in median annual crisis rate vs placebo |
| L-glutamine (Endari) | 2017 | Reduction of acute complications of SCD (age 5 and older) | Phase 3 randomized trial | Number of pain crises over 48 weeks | Fewer crises (median 3 vs 4) and fewer hospitalizations vs placebo |
| Voxelotor (Oxbryta) | 2019 (voluntarily withdrawn 2024) | Hemoglobin S polymerization inhibitor for SCD | HOPE | Hemoglobin response (increase >1 g/dL) at 24 weeks | 51% achieved a >1 g/dL hemoglobin increase vs 7% placebo; withdrawn 2024 over safety concerns |
| Crizanlizumab (Adakveo) | 2019 | Prevention of vaso-occlusive crises (age 16 and older) | SUSTAIN | Annual rate of vaso-occlusive crises | ~45% lower median annual VOC rate vs placebo (1.63 vs 2.98) |
| Exagamglogene autotemcel (exa-cel) (Casgevy) | 2023 | One-time CRISPR/Cas9 gene-edited autologous therapy for severe SCD with recurrent VOCs (age 12+) | CLIMB SCD-121 | Freedom from severe VOCs for at least 12 consecutive months | ~29 of 30 evaluable patients (about 97%) VOC-free for at least 12 months |
| Lovotibeglogene autotemcel (lovo-cel) (Lyfgenia) | 2023 | One-time lentiviral gene-addition autologous therapy for SCD with history of VOEs (age 12+) | HGB-206 (Group C) | Complete resolution of vaso-occlusive events (6-18 months) | Complete resolution of VOEs in ~88% (28/32) of evaluable patients |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in sickle cell disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Voxelotor — Post-approval safety review (HOPE and post-marketing data) | Voluntarily withdrawn from all markets in 2024 | Imbalance in vaso-occlusive crises and deaths suggested overall benefit no longer outweighed risk despite hemoglobin gains |
| Rivipansel (pan-selectin inhibitor) — RESET | Failed to meet primary and key secondary endpoints for treating acute vaso-occlusive crisis | No significant reduction in time to crisis readiness for discharge; possible late dosing after crisis onset |
| Prasugrel — DOVE | Failed to significantly reduce vaso-occlusive crisis rate in children with SCD | Antiplatelet approach did not meet its primary endpoint despite biologic rationale |
Choosing the right endpoint
Primary endpoints that matter in sickle cell disease trials
- Vaso-occlusive crisis (VOC) rate — Annualized frequency of painful crises; the central efficacy endpoint for disease-modifying and preventive therapies
- Freedom from severe VOCs (12 months) — Durable absence of crises used as the primary curative-intent endpoint for gene therapies
- Hemoglobin response — Increase in hemoglobin (e.g., >1 g/dL) reflecting reduced hemolysis, used for oxygen-affinity modulators
- Transfusion independence — Freedom from chronic transfusion support, a key durable benefit measure especially in gene therapy
How iNGENū runs sickle cell disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Sickle Cell Disease clinical trials — FAQs
What is the foundational drug therapy for SCD?
What changed with the 2023 gene therapy approvals?
Why was voxelotor (Oxbryta) withdrawn?
Ready to discuss your sickle cell disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal